A prospective observational safety study of patients with BRAF V600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

P. G. Corrie; P. Terheyden; A. J. ten Tije; R. Herbst; R. Jansen; M. Marples; D. Debus; R. Marconcini; M. Blasinska-Morawiec; K. Freivogel; M. L.G. Munson; G. R. Goodman; J. J. Hsu; N. Sadetsky; D. Colburn; P. Rutkowski

Article

A prospective observational safety study of patients with BRAF V600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

British Journal of Dermatology

DOI: 10.1111/bjd.17465

3Citations

7Readers

Get full text

Cite

CITATION STYLE

APA

Corrie, P. G., Terheyden, P., ten Tije, A. J., Herbst, R., Jansen, R., Marples, M., … Rutkowski, P. (2019, May 1). A prospective observational safety study of patients with BRAF V600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). British Journal of Dermatology. Blackwell Publishing Ltd. https://doi.org/10.1111/bjd.17465

A prospective observational safety study of patients with BRAF V600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

Cite

Register to see more suggestions